Device Trial Radar · NCT04369833
Development of Continuous Glucose Monitoring System Cohort for Personalized Diabetes Prevention and Management Platform
Last checked: Nov 19, 2026Latest source record: May 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
130
Actual
Start
May 11, 2020
Primary completion
Sep 30, 2020
Study completion Sep 30, 2020
Sponsor
- Lead sponsor
- Pusan National University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 30, 2020
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to collect a variety of clinical data and blood glucose changes using a continuous glucose monitoring device for high-risk diabetes patients (prediabetes) in order to develop a personalized diabetes prevention and management platform based on artificial intelligence model using mathematical analysis.
Conditions
- PreDiabetes
- Glucose Metabolism Disorders
- Diabetes Mellitus
Interventions
continuous glucose monitoring systemDevice
wearing continuous glucose monitoring device (iPro2 professional continuous glucose monitoring, MedtronicⓇ, California, USA)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Insulin ResistanceTime frame: 1 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pusan national university hospital
Busan, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.